Drug
Regn17372 Linvoseltamab
Regn17372 Linvoseltamab: highest development phase Phase 1/2, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| REGN17372+Linvoseltamab NCT07455851 | Phase 1/2 | Relapsed Refractory Multiple Myeloma (RRMM) |
Latest
No recent events.
Follow Regn17372 Linvoseltamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.